Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36348   clinical trials with a EudraCT protocol, of which   5989   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib

    Summary
    EudraCT number
    2013-002134-21
    Trial protocol
    DE   ES   IT   NL   DK   AT   BE   SE  
    Global end of trial date
    29 Feb 2016

    Results information
    Results version number
    v1(current)
    This version publication date
    29 Jun 2017
    First version publication date
    29 Jun 2017
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    AP26113-13-201
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02094573
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Takeda Development Center Americas, Inc.
    Sponsor organisation address
    One Takeda Parkway, Deerfield, IL, United States, 60015
    Public contact
    Medical Director, Takeda Development Center Americas, Inc., +1 877-825-3327, clinicaltrialregistry@tpna.com
    Scientific contact
    Medical Director, Takeda Development Center Americas, Inc., +1 877-825-3327, clinicaltrialregistry@tpna.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    29 Feb 2016
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    29 Feb 2016
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the efficacy and safety of two different dosing regimens of brigatinib (AP26113) in participants with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with crizotinib.
    Protection of trial subjects
    All study participants were required to read and sign an Informed Consent Form.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    04 Jun 2014
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety, Efficacy
    Long term follow-up duration
    2 Years
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 9
    Country: Number of subjects enrolled
    Austria: 9
    Country: Number of subjects enrolled
    Belgium: 5
    Country: Number of subjects enrolled
    Canada: 3
    Country: Number of subjects enrolled
    Denmark: 8
    Country: Number of subjects enrolled
    France: 6
    Country: Number of subjects enrolled
    Germany: 14
    Country: Number of subjects enrolled
    Hong Kong: 6
    Country: Number of subjects enrolled
    Italy: 29
    Country: Number of subjects enrolled
    Netherlands: 12
    Country: Number of subjects enrolled
    Norway: 2
    Country: Number of subjects enrolled
    Singapore: 7
    Country: Number of subjects enrolled
    Korea, Republic of: 46
    Country: Number of subjects enrolled
    Spain: 12
    Country: Number of subjects enrolled
    Sweden: 4
    Country: Number of subjects enrolled
    Switzerland: 1
    Country: Number of subjects enrolled
    United Kingdom: 3
    Country: Number of subjects enrolled
    United States: 46
    Worldwide total number of subjects
    222
    EEA total number of subjects
    104
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    170
    From 65 to 84 years
    52
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Participants took part in the study at 94 investigative sites in the United States, Canada, Europe, Australia and Asia from 04 Jun 2014 up to clinical cut-off date 29 Feb 2016. Study is ongoing.

    Pre-assignment
    Screening details
    Participants with ALK-positive, locally advanced or metastatic NSCLC who were treated with crizotinib were enrolled to receive AP26113 90 mg, once daily or AP26113 90-180 mg, once daily.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Brigatinib 90 mg
    Arm description
    Brigatinib 90 mg, tablets, orally, once daily in each cycle of 28 days until disease progression or intolerable toxicity.
    Arm type
    Experimental

    Investigational medicinal product name
    Brigatinib
    Investigational medicinal product code
    AP26113
    Other name
    Pharmaceutical forms
    Capsule, Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    AP26113 tablets and capsules

    Arm title
    Brigatinib 90 mg - 180 mg
    Arm description
    Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by AP26113 180 mg, orally once daily in Cycle 1 of 28 days followed by AP26113 180 mg, orally once daily in cycle 2 and onward cycles of 28 days until disease progression or intolerable toxicity.
    Arm type
    Experimental

    Investigational medicinal product name
    Brigatinib
    Investigational medicinal product code
    AP26113
    Other name
    Pharmaceutical forms
    Capsule, Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    AP26113 tablets and capsules

    Number of subjects in period 1
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Started
    112
    110
    Treated
    109
    110
    Completed
    0
    0
    Not completed
    112
    110
         Randomized but not treated
    3
    -
         Non-compliance with study drug
    -
    1
         Adverse event, serious fatal
    7
    1
         Clinical Progressive Disease
    4
    3
         Adverse event, non-fatal
    3
    9
         Documented Progressive Disease
    29
    16
         Ongoing
    64
    76
         Consent withdrawn by subject
    2
    4

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Brigatinib 90 mg
    Reporting group description
    Brigatinib 90 mg, tablets, orally, once daily in each cycle of 28 days until disease progression or intolerable toxicity.

    Reporting group title
    Brigatinib 90 mg - 180 mg
    Reporting group description
    Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by AP26113 180 mg, orally once daily in Cycle 1 of 28 days followed by AP26113 180 mg, orally once daily in cycle 2 and onward cycles of 28 days until disease progression or intolerable toxicity.

    Reporting group values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg Total
    Number of subjects
    112 110 222
    Age Categorical
    Units: Subjects
        18-49 years
    50 33 83
        50-64 years
    40 47 87
        65-74 years
    20 23 43
        ≥75 years
    2 7 9
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    51.5 ± 13.01 55.5 ± 12.96 -
    Gender, Male/Female
    Units: Subjects
        Female
    62 64 126
        Male
    50 46 96
    Race/Ethnicity, Customized
    Units: Subjects
        White
    72 76 148
        Black or African American
    1 2 3
        Asian
    39 30 69
        Unknown
    0 2 2
    Race/Ethnicity, Customized
    Units: Subjects
        Hispanic or Latino
    5 8 13
        Not Hispanic or Latino
    107 102 209
    Region of Enrollment
    Units: Subjects
        Australia
    3 6 9
        Austria
    3 6 9
        Belgium
    3 2 5
        Canada
    2 1 3
        Denmark
    2 6 8
        France
    4 2 6
        Germany
    7 7 14
        Hong Kong
    6 0 6
        Italy
    15 14 29
        Netherlands
    6 6 12
        Norway
    1 1 2
        Singapore
    4 3 7
        Spain
    5 7 12
        Sweden
    2 2 4
        Switzerland
    0 1 1
        United Kingdom
    2 1 3
        United States
    21 25 46
        Korea, Republic Of
    26 20 46

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Brigatinib 90 mg
    Reporting group description
    Brigatinib 90 mg, tablets, orally, once daily in each cycle of 28 days until disease progression or intolerable toxicity.

    Reporting group title
    Brigatinib 90 mg - 180 mg
    Reporting group description
    Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by AP26113 180 mg, orally once daily in Cycle 1 of 28 days followed by AP26113 180 mg, orally once daily in cycle 2 and onward cycles of 28 days until disease progression or intolerable toxicity.

    Primary: Confirmed Objective Response Rate (ORR) as Assessed by Investigator

    Close Top of page
    End point title
    Confirmed Objective Response Rate (ORR) as Assessed by Investigator [1]
    End point description
    ORR assessed by investigator, defined as proportion of participants with confirmed Complete response (CR)/partial response (PR) per Response Evaluation Criteria in Solid tumors (RECIST) v1.1 (confirmed ≥4 weeks after initial response), after initiation of study treatment. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to <10 mm in short axis. CR for non-target lesion: disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (<10mm short axis) and normalization of tumor marker level. PR: at least 30% decrease in sum of longest diameters (SLD) of target lesions, taking as reference baseline sum diameters. Intention to Treat (ITT) Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to assigned dose.
    End point type
    Primary
    End point timeframe
    Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered cycle) through 15 cycles and every 3 cycles thereafter until disease progression or up to data cut-off date: 29 Feb 2016 (approximately up to 20 months)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Statistical Analysis not reported for this endpoint.
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    112
    110
    Units: percentage of participants
        number (confidence interval 97.5%)
    44.6 (34 to 55.6)
    53.6 (42.6 to 64.5)
    No statistical analyses for this end point

    Secondary: Confirmed Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC)

    Close Top of page
    End point title
    Confirmed Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC)
    End point description
    ORR assessed by the IRC, is defined as the proportion of the participants with confirmed Clinical response (CR) or partial response (PR) according to RECIST v1.1 (confirmed ≥4 weeks after initial response), after the initiation of study treatment. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to <10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline sum diameters. The exact 2-sided 95% confidence interval was calculated. ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose.
    End point type
    Secondary
    End point timeframe
    Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered cycle) through 15 cycles and every 3 cycles thereafter until disease progression or up to data cut-off date: 29 Feb 2016 (approximately up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    112
    110
    Units: percentage of participants
        number (confidence interval 95%)
    48.2 (38.7 to 57.9)
    52.7 (43 to 62.3)
    No statistical analyses for this end point

    Secondary: Confirmed Intracranial Central Nervous System Objective Response Rate (CNS ORR) in Participants with Measurable Active Brain Metastases

    Close Top of page
    End point title
    Confirmed Intracranial Central Nervous System Objective Response Rate (CNS ORR) in Participants with Measurable Active Brain Metastases
    End point description
    Confirmed intracranial CNS ORR is defined as proportion of participants with CR or PR in intracranial CNS per modification of RECIST v1.1 as evaluated by IRC after initiation of study drug. Confirmed responses were those that persisted on repeat imaging 4 weeks or more after initial response. CR for target lesion: disappearance of extranodal non-target lesions, lymph nodes must be non-pathological in size (<10mm short axis). CR for non-target lesion: disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (<10mm short axis) and normalization of tumor marker level. PR: at least a 30% decrease in sum of longest diameters (SLD) of target lesions, taking as reference the baseline sum diameters. ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to assigned dose. Participants with measurable active brain metastases at baseline were evaluated for this endpoint.
    End point type
    Secondary
    End point timeframe
    Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered cycle) through 15 cycles and every 3 cycles thereafter until disease progression or up to data cut-off date:29 Feb 2016 (approximately up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    19
    15
    Units: percentage of participants
    number (confidence interval 95%)
        CNS ORR
    42.1 (20.3 to 66.5)
    73.3 (44.9 to 92.2)
    No statistical analyses for this end point

    Secondary: Intracranial CNS Progression Free Survival (PFS) in Participants with Active Brain Metastases

    Close Top of page
    End point title
    Intracranial CNS Progression Free Survival (PFS) in Participants with Active Brain Metastases
    End point description
    Intracranial CNS PFS as evaluated by IRC is defined as the time interval from the date of the first dose of the study drug until the first date at which intracranial CNS disease progression, an increase of 20% or more in the sum of diameters of intracranial CNS target lesions, unequivocal progression of non-target lesions, or the appearance of new lesions in the intracranial CNS, was objectively documented by a scan, or death due to any cause, whichever occurred first. ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose. Participants with active brain metastases at baseline were evaluated for this outcome measure. 99999 = Not applicable as upper limit of PFS was not reached.
    End point type
    Secondary
    End point timeframe
    Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered cycle) through 15 cycles and every 3 cycles thereafter until disease progression or up to data cut-off date: 29 Feb 2016 (approximately up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    51
    51
    Units: months
        median (confidence interval 95%)
    15.6 (7.3 to 15.7)
    11.1 (7.4 to 99999)
    No statistical analyses for this end point

    Secondary: Time to Response

    Close Top of page
    End point title
    Time to Response
    End point description
    Time to response is defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to <10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline sum diameters. ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose. Participants who had confirmed CR or PR were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Up to data cut-off date: 29 Feb 2016 (approximately up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    50
    59
    Units: months
        median (confidence interval 95%)
    1.8 (1.7 to 9.1)
    1.9 (1 to 11)
    No statistical analyses for this end point

    Secondary: Duration of Response

    Close Top of page
    End point title
    Duration of Response
    End point description
    Duration of response is defined as time interval from time that measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that progressive disease is objectively documented or death. Patients without progressive disease or death were censored at the last valid response assessment. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to <10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in SLD of target lesions, taking as reference the baseline sum diameters. ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose. Participants who had confirmed CR or PR were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Up to data cut-off date: 29 Feb 2016 (approximately up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    50
    59
    Units: months
        median (confidence interval 95%)
    13.8 (5.6 to 13.8)
    11.1 (9.2 to 13.8)
    No statistical analyses for this end point

    Secondary: Time on Treatment

    Close Top of page
    End point title
    Time on Treatment
    End point description
    Time on treatment is defined as the time from the first to the last dose of study drug. For participants who have not discontinued, time on treatment was censored as of the last dose of the study drug. Safety population included all participants who received at least one dose of study drug.
    End point type
    Secondary
    End point timeframe
    Up to data cut-off date: 29 Feb 2016 (approximately up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    109
    110
    Units: days
        arithmetic mean (standard deviation)
    231.6 ± 129.19
    251.9 ± 137.93
    No statistical analyses for this end point

    Secondary: Disease Control Rate

    Close Top of page
    End point title
    Disease Control Rate
    End point description
    Disease control rate (DCR) is defined as the proportion of randomized participants who were confirmed to have achieved CR or PR or have a best overall response as stable disease (SD) for 6 weeks or more after initiation of the study drug. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to <10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose.
    End point type
    Secondary
    End point timeframe
    Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered cycle) through 15 cycles and every 3 cycles thereafter until disease progression or up to data cut-off date: 29 Feb 2016 (approximately up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    112
    110
    Units: percentage of participants
        number (confidence interval 95%)
    82.1 (73.8 to 88.7)
    86.4 (78.5 to 92.2)
    No statistical analyses for this end point

    Secondary: Progression Free Survival (PFS)

    Close Top of page
    End point title
    Progression Free Survival (PFS)
    End point description
    PFS is defined as the time interval from the date of the first dose of the study treatment until the first date at which disease progression is objectively documented, or death due to any cause, whichever occurs first. Disease progression for target lesion: SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest) and SLD must also demonstrate an absolute increase of at least 5 mm or development of any new lesion. Disease progression for non-target lesion: Unequivocal progression of existing non-target lesions. (Subjective judgment by experienced reader). ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose. 99999 = Not applicable, upper limit of PFS was not reached.
    End point type
    Secondary
    End point timeframe
    Up to data cut-off date: 29 Feb 2016 (approximately up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    112
    110
    Units: months
        median (confidence interval 95%)
    9.2 (7.4 to 15.6)
    12.9 (11.1 to 99999)
    No statistical analyses for this end point

    Secondary: Overall Survival (OS)

    Close Top of page
    End point title
    Overall Survival (OS)
    End point description
    OS is defined as the time interval from the date of the first dose of the study treatment until death due to any cause. ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose. 9999 = Not applicable, The median OS and 95% CI were not reached due to relatively lower number of deaths occurred by the time of clinical cut-off date.
    End point type
    Secondary
    End point timeframe
    Up to data cut-off date: 29 Feb 2016 (approximately up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    112
    110
    Units: months
    median (full range (min-max))
        Overall Survival
    9999 (9999 to 9999)
    9999 (9999 to 9999)
        1 Year Overall Survival
    70.6 (59.8 to 79.1)
    79.5 (66.9 to 87.7)
    No statistical analyses for this end point

    Secondary: Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE)

    Close Top of page
    End point title
    Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE)
    End point description
    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
    End point type
    Secondary
    End point timeframe
    From first dose of study drug up to 30 days following the last dose of study drug (up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    109
    110
    Units: participants
    106
    110
    No statistical analyses for this end point

    Secondary: Pre-dose Brigatinib Plasma Concentration

    Close Top of page
    End point title
    Pre-dose Brigatinib Plasma Concentration
    End point description
    ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose. Here, number of participants analyzed is the participants who were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Day 1 Cycle 1 pre-dose; Cycle 2 pre-dose and at multiple time points (up to 6-8 hours) post dose; Cycles 3, 4 and 5 pre-dose and at 1-8 hours post dose
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    112
    110
    Units: ng/ml
    arithmetic mean (standard deviation)
        Cycle 2 (n=101, 97)
    295.2 ± 252
    520 ± 321.9
        Cycle 3 (n=91, 92)
    263.9 ± 238.9
    537 ± 360.3
        Cycle 4 (n=80, 87)
    236.1 ± 188
    564.7 ± 415
        Cycle 5 (n=80, 79)
    256.4 ± 282.3
    579.7 ± 396.7
    No statistical analyses for this end point

    Secondary: Patient-reported Symptoms Global Health Status/Quality of Life (QoL) Scores

    Close Top of page
    End point title
    Patient-reported Symptoms Global Health Status/Quality of Life (QoL) Scores
    End point description
    Patient-reported symptoms global health status/QoL scores were based on questions 29 and 30 of EORTC QLQ-C30. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales; 3 symptom scales; Last 2 questions on global health status/QoL scale are coded on 7-point scale (1=very poor-7=excellent). 6 single-item scales also are included. Raw scores for multi-item scales and single-item measures will be linearly transformed to obtain score ranging from 0-100, where higher score = a higher level of functioning. ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to assigned dose. Here, n represents number of participants evaluable at specific time point. 99999 = No or only one participant was analyzed for time point.
    End point type
    Secondary
    End point timeframe
    Up to 30 days after the last dose of study drug or up to data cut-off date: 29 Feb 2016 (approximately up to 20.2 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    112
    110
    Units: unit on a scale
    arithmetic mean (standard deviation)
        Baseline (n=108, 108)
    52.39 ± 27.42
    58.49 ± 23.4
        Cycle 2 (n=101, 97)
    64.19 ± 20.73
    65.72 ± 19.54
        Cycle 3 (n=91, 91)
    65.57 ± 24.06
    68.5 ± 20.52
        Cycle 4 (n=84, 89)
    69.44 ± 20.59
    66.95 ± 20.89
        Cycle 5 (n=82, 84)
    70.12 ± 20.28
    72.12 ± 17.57
        Cycle 6 (n=78, 81)
    69.76 ± 20.02
    71.5 ± 18.63
        Cycle 7 (n=75, 76)
    67.56 ± 20.53
    71.05 ± 19.88
        Cycle 8 (n=61, 70)
    66.12 ± 22.46
    70.95 ± 19.95
        Cycle 9 (n=53, 57)
    67.77 ± 22.82
    70.32 ± 19.48
        Cycle 10 (n=42, 47)
    69.64 ± 22.07
    68.97 ± 22.43
        Cycle 11 (n=29, 39)
    69.54 ± 21.97
    69.87 ± 22.43
        Cycle 12 (n=26, 33)
    60.9 ± 24.47
    73.48 ± 23.15
        Cycle 13 (n=20, 27)
    65 ± 20.52
    74.07 ± 21.72
        Cycle 14 (n=15, 22)
    62.22 ± 24.57
    73.11 ± 22.56
        Cycle 15 (n=12, 17)
    64.58 ± 25.41
    74.02 ± 24.81
        Cycle 16 (n=9,12)
    64.81 ± 27.25
    74.31 ± 18.62
        Cycle 17 (n=4, 7)
    75 ± 11.79
    75 ± 24.06
        Cycle 18 (n=1, 5)
    100 ± 999999
    78.33 ± 21.73
        Cycle 19 (n=0, 2)
    999999 ± 999999
    66.67 ± 47.14
        Cycle 20 (n=0,2)
    999999 ± 999999
    70.83 ± 41.25
        Cycle 21 (n=0,2)
    999999 ± 999999
    62.5 ± 5.89
        End of Treatment (n=30, 12)
    37.78 ± 25.87
    48.61 ± 13.69
        Follow-Up 30 Days After Last Dose (n=11, 10)
    43.94 ± 32.93
    60 ± 15.61
    No statistical analyses for this end point

    Secondary: Confirmed Intracranial Central Nervous System Objective Response Rate (CNS ORR) in Participants with Only Non-measurable Active Brain Metastases

    Close Top of page
    End point title
    Confirmed Intracranial Central Nervous System Objective Response Rate (CNS ORR) in Participants with Only Non-measurable Active Brain Metastases
    End point description
    Confirmed intracranial CNS ORR: defined as proportion of participants with CR or PR in intracranial CNS per modification of RECIST v1.1 as evaluated by IRC after initiation of study drug. Confirmed responses were those that persisted on repeat imaging 4 weeks or more after initial response. CR for target lesion: disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (<10mm short axis). CR for non-target lesion: disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in SLD of target lesions, taking as reference the baseline sum diameters. ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose. Participants with only non-measurable active brain metastases at baseline were evaluated for this endpoint.
    End point type
    Secondary
    End point timeframe
    Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered cycle) through 15 cycles and every 3 cycles thereafter until disease progression or up to data cut-off date:29 Feb 2016 (approximately up to 20 months)
    End point values
    Brigatinib 90 mg Brigatinib 90 mg - 180 mg
    Number of subjects analysed
    32
    36
    Units: percentage of participants
        number (confidence interval 95%)
    9.4 (2 to 25)
    19.4 (8.2 to 36)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose of study drug up to 30 days following the last dose of study drug or up to data cut-off date: 29 Feb 2016 (approximately up to 20.2 months)
    Adverse event reporting additional description
    At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    12.0
    Reporting groups
    Reporting group title
    AP26113 90 mg - 180 mg
    Reporting group description
    AP26113 90 mg, tablets, orally, once daily for 7 days followed by AP26113 180 mg, orally once daily in Cycle 1 of 28 days followed by AP26113 180 mg, orally once daily in cycle 2 and onward cycles of 28 days until disease progression or intolerable toxicity.

    Reporting group title
    AP26113 90 mg
    Reporting group description
    AP26113 90 mg, tablets, orally, once daily in each cycle of 28 days until disease progression or intolerable toxicity.

    Serious adverse events
    AP26113 90 mg - 180 mg AP26113 90 mg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    44 / 110 (40.00%)
    41 / 109 (37.61%)
         number of deaths (all causes)
    1
    0
         number of deaths resulting from adverse events
    1
    0
    Vascular disorders
    Peripheral Artery Stenosis
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Neoplasm Progression
         subjects affected / exposed
    5 / 110 (4.55%)
    13 / 109 (11.93%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 14
         deaths causally related to treatment / all
    0 / 5
    0 / 10
    Malignant Pleural Effusion
         subjects affected / exposed
    3 / 110 (2.73%)
    3 / 109 (2.75%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Metastases To Central Nervous System
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metastases To Meninges
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    General disorders and administration site conditions
    General Physical Health Deterioration
         subjects affected / exposed
    1 / 110 (0.91%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device Occlusion
         subjects affected / exposed
    1 / 110 (0.91%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Asthenia
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sudden Death
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Infusion Site Thrombosis
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Confusional State
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Post Procedural Haemorrhage
         subjects affected / exposed
    2 / 110 (1.82%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Head Injury
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Laceration
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Radiation Necrosis
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Radiation Pneumonitis
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Neutrophil Count Decreased
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pneumonitis
         subjects affected / exposed
    8 / 110 (7.27%)
    2 / 109 (1.83%)
         occurrences causally related to treatment / all
    8 / 8
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary Embolism
         subjects affected / exposed
    2 / 110 (1.82%)
    2 / 109 (1.83%)
         occurrences causally related to treatment / all
    0 / 2
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Dyspnoea
         subjects affected / exposed
    2 / 110 (1.82%)
    2 / 109 (1.83%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Dyspnoea Exertional
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleural Effusion
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemoptysis
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory Failure
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Nervous system disorders
    Epilepsy
         subjects affected / exposed
    1 / 110 (0.91%)
    3 / 109 (2.75%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dysaesthesia
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebrovascular Accident
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Generalised Tonic-Clonic Seizure
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous System Disorder
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Simple Partial Seizures
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spinal Cord Compression
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Transient Ischaemic Attack
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    Macular Oedema
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vertigo Positional
         subjects affected / exposed
    0 / 110 (0.00%)
    2 / 109 (1.83%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal Pain
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Food Poisoning
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal Haemorrhage
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Small Intestinal Obstruction
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholangitis Acute
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Jaundice Cholestatic
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Renal Impairment
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hydronephrosis
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Dermatitis Allergic
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Angioedema
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Paraneoplastic Dermatomyositis
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rash
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back Pain
         subjects affected / exposed
    1 / 110 (0.91%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arthralgia
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neck Pain
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pathological Fracture
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Appendicitis
         subjects affected / exposed
    1 / 110 (0.91%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    8 / 110 (7.27%)
    3 / 109 (2.75%)
         occurrences causally related to treatment / all
    1 / 9
    0 / 3
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    Bronchitis
         subjects affected / exposed
    1 / 110 (0.91%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atypical Pneumonia
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Meningitis Bacterial
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Tuberculous Pleurisy
         subjects affected / exposed
    1 / 110 (0.91%)
    0 / 109 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    0 / 110 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    AP26113 90 mg - 180 mg AP26113 90 mg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    103 / 110 (93.64%)
    103 / 109 (94.50%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    23 / 110 (20.91%)
    12 / 109 (11.01%)
         occurrences all number
    41
    15
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    30 / 110 (27.27%)
    22 / 109 (20.18%)
         occurrences all number
    41
    28
    Pyrexia
         subjects affected / exposed
    7 / 110 (6.36%)
    15 / 109 (13.76%)
         occurrences all number
    11
    34
    Asthenia
         subjects affected / exposed
    11 / 110 (10.00%)
    9 / 109 (8.26%)
         occurrences all number
    18
    10
    Oedema Peripheral
         subjects affected / exposed
    8 / 110 (7.27%)
    7 / 109 (6.42%)
         occurrences all number
    9
    9
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    8 / 110 (7.27%)
    12 / 109 (11.01%)
         occurrences all number
    8
    13
    Investigations
    Blood Creatine Phosphokinase Increased
         subjects affected / exposed
    33 / 110 (30.00%)
    12 / 109 (11.01%)
         occurrences all number
    77
    27
    Amylase Increased
         subjects affected / exposed
    16 / 110 (14.55%)
    9 / 109 (8.26%)
         occurrences all number
    22
    18
    Aspartate Aminotransferase Increased
         subjects affected / exposed
    16 / 110 (14.55%)
    9 / 109 (8.26%)
         occurrences all number
    18
    12
    Lipase Increased
         subjects affected / exposed
    13 / 110 (11.82%)
    8 / 109 (7.34%)
         occurrences all number
    22
    13
    Alanine Aminotransferase Increased
         subjects affected / exposed
    10 / 110 (9.09%)
    9 / 109 (8.26%)
         occurrences all number
    14
    9
    Neutrophil Count Decreased
         subjects affected / exposed
    5 / 110 (4.55%)
    6 / 109 (5.50%)
         occurrences all number
    7
    10
    Blood Lactate Dehydrogenase Increased
         subjects affected / exposed
    9 / 110 (8.18%)
    2 / 109 (1.83%)
         occurrences all number
    11
    2
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    37 / 110 (33.64%)
    20 / 109 (18.35%)
         occurrences all number
    47
    31
    Dyspnoea
         subjects affected / exposed
    21 / 110 (19.09%)
    21 / 109 (19.27%)
         occurrences all number
    30
    28
    Oropharyngeal Pain
         subjects affected / exposed
    7 / 110 (6.36%)
    8 / 109 (7.34%)
         occurrences all number
    7
    8
    Dysphonia
         subjects affected / exposed
    6 / 110 (5.45%)
    5 / 109 (4.59%)
         occurrences all number
    8
    17
    Productive Cough
         subjects affected / exposed
    4 / 110 (3.64%)
    5 / 109 (4.59%)
         occurrences all number
    6
    5
    Haemoptysis
         subjects affected / exposed
    6 / 110 (5.45%)
    2 / 109 (1.83%)
         occurrences all number
    0
    0
    Dyspnoea Exertional
         subjects affected / exposed
    2 / 110 (1.82%)
    6 / 109 (5.50%)
         occurrences all number
    2
    6
    Nervous system disorders
    Headache
         subjects affected / exposed
    30 / 110 (27.27%)
    30 / 109 (27.52%)
         occurrences all number
    50
    59
    Dizziness
         subjects affected / exposed
    9 / 110 (8.18%)
    10 / 109 (9.17%)
         occurrences all number
    9
    14
    Peripheral Sensory Neuropathy
         subjects affected / exposed
    7 / 110 (6.36%)
    5 / 109 (4.59%)
         occurrences all number
    9
    5
    Paraesthesia
         subjects affected / exposed
    7 / 110 (6.36%)
    10 / 109 (9.17%)
         occurrences all number
    9
    12
    Memory Impairment
         subjects affected / exposed
    6 / 110 (5.45%)
    2 / 109 (1.83%)
         occurrences all number
    6
    3
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    10 / 110 (9.09%)
    2 / 109 (1.83%)
         occurrences all number
    0
    0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    42 / 110 (38.18%)
    21 / 109 (19.27%)
         occurrences all number
    120
    28
    Nausea
         subjects affected / exposed
    44 / 110 (40.00%)
    36 / 109 (33.03%)
         occurrences all number
    60
    64
    Constipation
         subjects affected / exposed
    17 / 110 (15.45%)
    21 / 109 (19.27%)
         occurrences all number
    27
    25
    Vomiting
         subjects affected / exposed
    25 / 110 (22.73%)
    26 / 109 (23.85%)
         occurrences all number
    56
    47
    Stomatitis
         subjects affected / exposed
    8 / 110 (7.27%)
    4 / 109 (3.67%)
         occurrences all number
    12
    5
    Dyspepsia
         subjects affected / exposed
    6 / 110 (5.45%)
    7 / 109 (6.42%)
         occurrences all number
    8
    7
    Abdominal Pain
         subjects affected / exposed
    9 / 110 (8.18%)
    17 / 109 (15.60%)
         occurrences all number
    12
    21
    Dry Mouth
         subjects affected / exposed
    9 / 110 (8.18%)
    2 / 109 (1.83%)
         occurrences all number
    10
    2
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    6 / 110 (5.45%)
    0 / 109 (0.00%)
         occurrences all number
    6
    0
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    18 / 110 (16.36%)
    8 / 109 (7.34%)
         occurrences all number
    0
    0
    Dermatitis Acneiform
         subjects affected / exposed
    3 / 110 (2.73%)
    6 / 109 (5.50%)
         occurrences all number
    3
    7
    Pruritus
         subjects affected / exposed
    7 / 110 (6.36%)
    6 / 109 (5.50%)
         occurrences all number
    9
    6
    Musculoskeletal and connective tissue disorders
    Muscle Spasms
         subjects affected / exposed
    19 / 110 (17.27%)
    13 / 109 (11.93%)
         occurrences all number
    27
    20
    Arthralgia
         subjects affected / exposed
    15 / 110 (13.64%)
    15 / 109 (13.76%)
         occurrences all number
    19
    19
    Pain in extremity
         subjects affected / exposed
    4 / 110 (3.64%)
    12 / 109 (11.01%)
         occurrences all number
    5
    14
    Back Pain
         subjects affected / exposed
    17 / 110 (15.45%)
    10 / 109 (9.17%)
         occurrences all number
    20
    16
    Musculoskeletal Pain
         subjects affected / exposed
    9 / 110 (8.18%)
    4 / 109 (3.67%)
         occurrences all number
    12
    5
    Myalgia
         subjects affected / exposed
    9 / 110 (8.18%)
    6 / 109 (5.50%)
         occurrences all number
    12
    7
    Neck Pain
         subjects affected / exposed
    7 / 110 (6.36%)
    2 / 109 (1.83%)
         occurrences all number
    8
    2
    Musculoskeletal Chest Pain
         subjects affected / exposed
    7 / 110 (6.36%)
    5 / 109 (4.59%)
         occurrences all number
    12
    5
    Metabolism and nutrition disorders
    Decreased Appetite
         subjects affected / exposed
    17 / 110 (15.45%)
    24 / 109 (22.02%)
         occurrences all number
    23
    27
    Infections and infestations
    Upper Respiratory Tract Infection
         subjects affected / exposed
    6 / 110 (5.45%)
    8 / 109 (7.34%)
         occurrences all number
    7
    6
    Nasopharyngitis
         subjects affected / exposed
    9 / 110 (8.18%)
    9 / 109 (8.26%)
         occurrences all number
    14
    9
    Urinary Tract Infection
         subjects affected / exposed
    7 / 110 (6.36%)
    6 / 109 (5.50%)
         occurrences all number
    6
    8

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    03 Feb 2014
    • Adjusted study design to allow for randomization into two different study arms, each with a different dosing regimen (90 mg QD or 180 mg QD with a 7-day lead-in at 90 mg QD). • Increased enrollment projections to fill both study arms (and added at least 6 more months to accrue patients). • Updated statistical testing methods to address both study arms. • Updated clinical summary of data from the phase 1/2 study of brigatinib, including an assessment of the respiratory events and reports of early onset pulmonary syndrome. • Updated sections describing sampling for molecular genetic testing to allow for analysis of various tumor and plasma biomarkers as is feasible at different sites. • Updated tissue and blood sample procedures (described separately) to occur only at screening and end-of-treatment for molecular genetics, and added specifics for ALK FISH testing. • Updated PK collection procedures to include slightly more frequent sampling in Cycles 3, 4, and 5. • Updated Schedule of Events Table to include: randomization (on Day 1), a Day 8 visit, an assessment of brain MRI at screening, the addition of ALK FISH testing (at screening), adjustments to the descriptions of tissue and plasma sampling for molecular genetic testing, clarified the general description of assessments done every 8 weeks, and noted that an assessment of pulmonary symptoms should be performed during the visit on Day 8 and Day 15. • Updated dose modification sections (for TEAEs) to include separate recommendations for each study arm: one for Arm A and two for Arm B (one at 90 mg in the first 7 days and one after dose escalation to 180 mg). • Added a section on management of treatment-related early onset pulmonary syndrome and added updates to further clarify the section on management of treatment-related pneumonitis. • Added a section on re-escalation after dose modification. • Added a section describing Data Monitoring Committee.
    29 Jul 2014
    • Updated eligibility criteria to remove some restrictions on prior treatments, clarified restrictions for patients with CNS activity, and added an exclusion for pregnant/breastfeeding women. • Removed dietary restrictions based on clinical pharmacology testing results. • Allowed for adding a couple additional postbaseline time points for plasma biomarker sampling. • Updated the statistical sections to specify the analysis populations for efficacy and safety and clarified testing methodologies. • Updated the description of procedures, as follows: added a reminder to monitor for visual dysfunction, added creatine kinase to the blood draw assessments and specified that all glucose and insulin draws should be fasted, added more frequent pregnancy testing, and specified a two-hour window for the final PK time point. • Added guidelines for dose modifications (due to AEs) specific to QT prolongation, per the suggestion from a competent authority.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA